Company news
Omeros Corporation news in 2019
Omeros Corporation's news releases, calls and decks from 2019, newest first.
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
December 15, 2019
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
December 12, 2019
Omeros Announces Pricing of Upsized Public Offering of Common Stock
December 4, 2019
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
December 3, 2019
Omeros Announces Proposed Public Offering of Common Stock
December 3, 2019
Omeros Corporation Reports Third Quarter 2019 Financial Results
November 11, 2019
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
November 7, 2019
Omeros Scientists Win 2019 Prix Galien Research Award
November 6, 2019
Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019
November 5, 2019
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
November 3, 2019
Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
October 28, 2019
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
October 27, 2019
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
September 30, 2019
Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
September 24, 2019
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
September 15, 2019
FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
September 10, 2019